. .

DUBLIN, Jan. . 5, 2021 / PRNewswire / – The report, “Students and Workers, Non-Residential Housing, Global Market Report 2020-30: COVID-19 Impact and Recovery” has been added to ResearchAndMarkets. com offer.

Western Europe was the largest region in the global market for non-residential accommodation for students and workers with a market share of 29% in 2019. North America was the second largest region, accounting for 29% of the global non-residential market for students and workers. Africa was the smallest region in the global student and worker housing market.

Developers and designers are starting to focus on creating micro-housing units that offer housing options near universities at a reasonable price. Micro-enclosures provide students with miniature spaces for sleeping, studying, and preparing simple meals. With the increase in student enrollment and the workforce, micro-units cater to students and workers. Access to affordable housing. Many cities and countries are experimenting with micro-housing to meet the growing demand for affordable student and worker accommodation. For example, The Michaels Organization’s University Student Living is currently developing micro-units near Boston University ranging from 325 to 400 square feet, each with a private kitchen and bathroom.

The market for non-residential accommodation consists of the sale of non-residential accommodation and related goods by companies (organizations, sole proprietorships and partnerships) that operate bed and breakfast establishments and similar facilities, such as:. B.. Off-campus dormitories, residential clubs, and labor camps. These facilities offer temporary or long-term accommodation that can serve as a primary residence for the duration of the occupancy. These facilities can also offer additional services such as cleaning, catering and laundry services.

The global market for non-residential accommodation for students and employees is projected to reach $ 11 billion. USD 11 billion in 2019. USD grow. 4 billion in 2020 with a compound annual growth rate (CAGR) of 4. 1%. The low growth is mainly due to the economic slowdown in individual countries due to the COVID-19 outbreak and the measures taken to contain it. The market is then expected to recover and grow at a CAGR of 14% starting in 2021, reaching $ 16. 2 billion in 2023.

Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UNITED KINGDOM; UNITED STATES OF AMERICA; Venezuela; Vietnam

Relationship of market size and growth to related markets, GDP shares, expenditure per capita, comparison of indicators for non-residential accommodation of students and employees.

ResearchAndMarkets. com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Research and Markets Laura Wood, Senior Manager press @ researchandmarkets. com For E. . S.. . T Office Hours Call 1-917-300-0470 for U. S.. . / CAN Toll Free Call 1-800-526-8630 For GMT office hours call 353-1-416-8900 U. S.. . Fax: 646-607-1907 Fax (outside of U. . S.. . ): 353-1-481-1716

Edison Research named one of the races for Democrat Raphael Warnock, ousting reigning Kelly Loeffler, while Democratic challenger Jon Ossoff had 98% of the vote, a narrow margin over Republican David Perdue. A democratically controlled Senate would give President-elect Joe Biden more leeway to respond to his reform plans, including new COVID-19 incentives, but that could also mean higher corporate taxes and stricter regulations on the tech mega-caps – guidelines that usually not preferred by Wall Street.

Consolidation could soon be flying into the boardrooms of the major airlines to survive the COVID-19 pandemic.

Jagdeep Singh, founder of QuantumScape, speaks to Yahoo Finance after the company’s shares fell 40% Tuesday morning.

The Dow Jones futures were lower early Wednesday Tuesday as they watched the Georgia Senate runoff. Apple snapped back as JD passed a new buy point.

There is a growing feeling of relief among investors that the new year will be less volatile than 2020. That would be enough to boost sentiment, but even better is the perception that the markets will rise higher in the new year. Marko Kolanovic, the well-known quant expert at JPMorgan, sees the first stages of a positive feedback loop, where lower volatility and systematic investment strategies come together to generate profits, attract more investors – and according to Kolanovic the S&P 500 on 4. 600 to increase year-end. This corresponds to an increase in the index of 25%. Such a general market environment is sure to produce many stock winners, and Wall Street analysts are busy alerting them. Among other things, they are tapping into penny stocks, stocks priced below $ 5 per share. Their rock bottom makes Pennies the logical place to look for huge returns on investment. Although your risk factor is high, even a small gain in absolute terms turns into a massive percentage gain in the stock price. Using TipRanks’ database, we identified two penny stocks that pros believe could generate explosive profits in the coming months. Not to mention that everyone in the analyst community receives a consensus rating of “Strong Buy”. 9 Meter Biopharma (NMTR) Some biopharma companies take a broad-based approach while others focus on a niche. 9 meters is one of the latter, which is aimed at unmet needs of gastrointestinal patients. The company’s development pipeline includes drug candidates being studied for the treatment of short bowel syndrome (SBS) and celiac disease (CeD), two conditions that are both dangerous and difficult to treat. 9 Meters’ flagship Larazotide is in phase 3 development for the treatment of CeD. CeD affects about 1% of the population, but there are no approved therapies. The key data from the study are expected in the second half of 2021. In addition, last December, the company announced that it had entered into an agreement with EBRIS, the European Institute for Biomedical Research in Salerno, to study larazotide as a potential treatment for respiratory complications due to COVID-19. The other major drug in the company’s pipeline is NM-002 for SBS. The company recently announced positive Phase 1b / 2a results that have a measurable impact on disease symptoms in a compound that is well tolerated by patients. NMTR’s strong pipeline and $ 0. 89 stock quotes have received rave reviews from the pros on Wall Street. One of these NMTR bulls is Truist’s Srikripa Devarakonda. Quoting larazotide as a key component of his bullish thesis, the analyst noted, “We recognize that despite the encouragement of Ph2b data, investors will view a pivotal study in a hard-to-crack celiac program as high risk. We model an unadjusted / adjusted peak sales of 705 million. USD / 353 million. USD and see a potential plus of 400% – 1650% due to the positive Ph3 indicator. Devarakonda also sees “significant unmet need in SBS” and continues to believe that “NM-002 has a differentiated profile against it. SOC. Some of his key takeaways from the most recent Phase 1b / 2a results include: “1) We believe the drug showed early activity in SBS patients; All 9 patients showed a significant reduction in total stool volume. The mean TSO reduction was 42% from baseline. 2) reactions are rapid with effects on the TSO being observed within 48 hours of dosing; 3) Safety profile looks good, we want a longer service life. For this purpose, Devarakonda rates NMTR shares with a Buy and a price target of $ 5. This number shows his confidence in NMTR’s ability to grow 462% in the coming year. (To see Devarakonda’s track record, click here. ) If you now turn to the rest of the street, there are other analysts on the same side. With 4 buys and no holds or sells, the word on the street is that NMTR is a strong buy. Given its $ 4. 33 average target price, upside potential of 386% could be in stock for investors. (See NMTR stock analysis on TipRanks) Orchard Therapeutics (ORTX) Orchard Therapeutics takes a broad approach to the biopharmaceutical industry. The company is engaged in the development of gene therapies for rare, often incurable diseases, including neurometabolic disorders, primary immunodeficiency and blood disorders. The gene therapy approach uses blood stem cells to deliver corrected genetic information directly into the patient’s body. Orchard’s pipeline shows the diversity of gene therapy diseases – the company has no fewer than 12 drug candidates in development. Among these candidates, Libmeldy (OTL-200) stands out. Libmeldy is in the commercialization phase for the treatment of MLD (metachromatic leukodystrophy), a rare, mutation-based genetic disorder of the nervous system. Libmeldy, which was developed to treat children with adolescent forms of MLD by replacing the defective ARSA gene, received approval for medical use in the EU in December 2020. Wedbush analyst David Kidney Garden points to European approval of Libmeldy and its impact on Orchard’s progress. He writes: “We look forward to commercial execution of the company in the EU and eventual approval in the US in 2022. Last month, ORTX received IND approval from the FDA for the program, which paves the way for discussions with U.S. regulators to find an appropriate path for a BLA filing. “Net-net, with potentially two gene therapies approved in the next 12 to 18 months and a pivotal trial beginning in a third (MPS-I), we believe ORTX stocks are undervalued at these levels,” the analyst concluded. In line with his bullish comments, Kidney Garden rates ORTX as an outperform (i. e. Buy) and its target price of $ 15 indicate growth potential of 241% in the coming year. (Click here to view Kidney Garden’s success story. ) Do other analysts agree with Kidney Garden? Do it. In the last three months only buy ratings (3) were issued. Therefore ORTX receives a strong buy consensus rating. The average price target of $ 15 shows the stock could gain 241% over the coming year. (See ORTX stock analysis on TipRanks. ) To find great ideas for trading penny stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all of the insights into TipRanks stocks. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.

Wirecard, the insolvent German payment processor that overestimated cash on its balance sheet, rose again on Wednesday and extended its profits in the new year. Wirecard shares rose 16% on Wednesday after they more than doubled on Tuesday and rose 58% on Monday.

The emerging lidar company, Aeva, is led by two former Apple executives looking to shake up the industry.

The end of Bill Gross in late 2020 may have been more eventful than most of the others. The former Bond King not only spent the last few weeks of the year in Orange County, California. As a courthouse defending his right to distribute the Gilligan’s Island theme song from his Laguna Beach mansion, he also managed to ponder what he calls the “Bubblicious Stock Market”. On Sept. . 14 warned Gross that “there is little money to be made almost anywhere in the world” and urged investors to favor “shunned” areas such as tobacco, banks and foreign companies that are quoted on foreign exchange. Finally, he got down to the good stuff and re-examined the drivers of the market run-up, namely “intense speculation” and “fiscally pumped, central bank-prepared corporate earnings” when the Federal Reserve moved real rates close to zero.

I think investors deserve a lot better than to say there is no income opportunity in this market.

A Democratic victory in both Georgia runoffs could have a huge impact on tax and spending policies, the shape of the coronavirus recovery, and the outlook for stock markets.

Un Sac à Dos Intelligent ideas for travel and quotations. Un Design Minimaliste et une Fonctionnalité Moderne.

The greater likelihood of higher taxes and increased regulation from the Democratic-controlled Presidency and Congress resulted in lower trading in stock index futures.

Shares in Alibaba Group Holding Ltd – ADR (NYSE: BABA) closed Nov.. 5% on Tuesday, and at least one major options trader is betting that Alibaba will be back above $ 300 around that time next year. The Alibaba Deals: On Tuesday morning, Benzinga Pro subscribers received dozens of option notifications related to unusually large Alibaba option deals. Here are the three biggest ones: * At 10:00 AM. m. A dealer bought 1. 005 Alibaba call options with an exercise price of $ 300 expiring in January. Near the ask price at $ 20 in 2022. 485. The trade was about $ 2. 05 million bullish bet. * At 10:10 a.m.. m. A trader sold 300 Alibaba put options with an exercise price of $ 235, which expires in January. 2023 at an ask price of $ 54. 30th. The trade was about $ 1. 62 million bullish bet. * At 10:56 a.m.. m. A dealer bought 1. 000 Alibaba put options with an exercise price of $ 215 expiring in June. 18 for the price of $ 16. 60. The trade was about $ 1. Bearish bet of 66 million. Why It Matters: Even stocks-only traders often closely monitor options market activity for unusually large deals. Given the relative complexity of the options market, large options traders are typically viewed as more sophisticated than the average stock trader. Many of these large options traders are high net worth individuals or institutions who may have unique information or theses about the underlying stocks. Unfortunately, stock traders often use the options market to hedge against their larger equity positions, and there is no surefire way of telling whether an options trade is a stand-alone position or a hedge. In that case, given the relatively large size of Alibaba’s largest option deals on Tuesday, it could certainly be institutional hedge. Related link: Reading and Acting an Option Alert China’s Alibaba Raid: As strange as it sounds, much of Tuesday’s rally may have to do with a report from CNBC that Alibaba founder Jack Ma is safe and sound. China took action against Alibaba and its subsidiary Ant Financial after Ma made critical comments on Chinese government regulators in October. Ma has not performed publicly in months, leading some to speculate that the Chinese Communist Party imprisoned Ma, or worse, following his comments. While Alibaba is far from getting out of the woods in terms of government action, CNBC reported that Ma has simply lied and avoided the public since his controversial comments. BABA Chart from TradingView new TradingView. Widget ({“Width”: 680, “Height”: 423, “Icon”: “NYSE: BABA”, “Interval”: “D”, “Timezone”: “etc. / UTC “,” Topic “:” Light “,” style “:” 1 “,” locale “:” en “,” toolbar_bg “:” f1f3f6 “,” enable_publishing “: false,” allow_symbol_change “: true,” container_id “:” tradeview_b1d06 “}); Benzingas Take: The morning’s biggest Alibaba options trade was bullish, but the trade was generally mixed, with many traders taking the other side of the trade. The $ 2 million purchase has a break-even price of $ 320. 49 what 33 suggests. 5% up for the stock next year. See More From Benzinga * Click Here For Benzinga Option Deals * 2 Top Homebuilder Stocks For 2021 According To BofA * Why The Biden Administration Could Be Very Bullish For Ford, GM (C) 2021 Benzinga. com. Benzinga does not offer investment advice. All rights reserved.

Two analysts are raising their price targets on Apple shares, both noting strong demand for the new iPhone 12 line of phones.

A new year, a new addition to the stock portfolio – what could be more useful? The right time to buy is of course when the stocks are at the low end. Buying low and selling high may be a bit trite, but it’s true, and the truth has staying power. But the markets are on the up. The NASDAQ rose 43% in 2020 and the S&P 500 grew 16%. In such a market environment, finding stocks stuck in the doldrums is harder than it looks. This is where the Wall Street pros can help. We used TipRanks’ database to identify three stocks that fit a profile: a stock price that has fallen over 30% in the past 12 months but has at least double-digit upside potential according to analysts. Not to mention that everyone has received a moderate or strong buy consensus rating. Esperion (ESPR) We’re starting Esperion, a company that specializes in therapies to treat raised low-density lipoprotein cholesterol levels – a major contributor to heart disease. The company’s lead product, bempedoic acid, is now available in tablet form under the brand names Nexletol and Nexlizet. In February 2020, both Nexletol and Nexlizet were approved as oral treatments for lowering LDL-C. Bempedoic acid remains in clinical trials for its effectiveness in reducing the risk of cardiovascular disease. The study, called CLEAR Outcomes, is a large-scale long-term study in which more than 14. 000 patients will be recorded with top-line data, which is expected in the second half of 2022. The study includes 1. 400 locations in 32 countries worldwide. Esperion stock peaked last February following FDA approvals, but the stock has fallen since then. Stocks are down 65% from their high. Along with the decline in its share value, the company saw sales drop from Q2 to Q3, with sales of 212 million. USD fell to USD 3. 8 million. Since the Q3 report, Esperion announced pricing for a senior subordinated debt offering of 250 million. USD at a rate of 4% due in 2025. The offering gives the company a boost in available capital for further work on its development pipeline and marketing efforts for bempedoic acid. Chad Messer, who covers ESPR for Needham, sees the range of grades as positive for Esperion. “We believe this cash position will be enough to support Esperion through 2021 and profitability through 2022. . . We believe this funding should help address concerns about Esperion’s bottom line. Despite a challenging market launch of NEXLETOL and NEXLIZET, product growth continued in the third quarter against the background of a shrinking LDL-C market. This growth path suggests potential for rapid acceleration as conditions improve, “wrote Messer. To this end, Messer is giving ESPR stock a strong buy, and its price target of USD 158 suggests that the stock has room for tremendous growth this year – up to 481% from current levels. (To see Messer’s track record, click here. Overall, Esperion has 6 recent ratings with a breakdown of 5 buy and 1 hold to give the stock a strong buy rating based on analyst consensus. The shares trade at $ 27. 16, have an average target price of $ 63. 33, which is a year-long upward movement of 133%. (See ESPR stock analysis on TipRanks) Intercept Pharma (ICPT) Liver disease is a serious health threat, and Intercept Pharma is focused on developing therapies for some of the more dangerous chronic liver diseases, including non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Intercept has a research pipeline based on FXR, a regulator of the bile acid pathways in the liver system. The effect of FXR not only influences the bile acid metabolism, but also the glucose and lipid metabolism as well as inflammation and fibrosis in the liver. The lead compound obeticholic acid (OCA) is an analogue of the bile acid CDCA and as such may play a role in the FXR pathways and receptors involved in chronic liver disease. Treatment of liver disease by FXR biology has direct applications for PBC and shows promise in treating complications from NASH. ICPT shares fell sharply last summer when the FDA denied the company’s filing for approval of OCA for the treatment of NASH-related liver fibrosis. This delays the drug’s potential entry into a lucrative market. There is currently no treatment for NASH, and the first drug to get approved will come out on top in reaching a market estimated to have potential annual sales of $ 2 billion to $ 5 billion. The impact on the stock continues to be felt and the ICPT remains at its 52-week low. In response, Intercept announced significant changes in top-level management in December 2020 when CEO and President Mark Pruzanski announced that he would be joining. January this year resigns. He will be replaced by Jerome Durso, former COO of the company, who will also take up a position on the Board of Directors. Pruzanski remains an advisor and holds the position of director on the company’s board of directors. Piper Sandler analyst Yasmeen Rahimi takes an in-depth look at Intercept’s continued efforts to expand OCA applications and resubmit the new drug application to the FDA. She sees the change in leadership as part of this effort and writes: “[We] believe that Dr. . Pruzanski’s commitment to liver space transformation remains strong and he will continue to lead ICPT’s advances as an advisor and board member. Additionally, we have had the pleasure to work closely with Jerry Durso and believe that he will transform the company and guide ICPT’s success in growing the PBC market and leading the way to the potential approval and commercial introduction of OCA in NASH. Rahimi takes a long-term bullish stance on ICPT and gives the stock an overweight (i. e. Buy) and a target price of $ 82. This number shows an impressive upward trend of 220% for the next 12 months. (To see Rahimi’s track record, click here. ) Wall Street is a little more divided about the drug maker. ICPT’s moderate buying consensus rating is based on 17 ratings including 8 buys and 9 holds. The price of shares is $ 25. 82 and the average target price of $ 59. 19 suggests an upside of 132% over the next 12 months. (See ICPT stock analysis on TipRanks) Gilead Sciences (GILD) Gilead had a year like fireworks – fast up and fast down. The gains came in 1H20 when it was revealed that the company’s antiviral drug Remdesivir would become a top-notch treatment for COVID-19. By November, even though remdesivir was approved, the World Health Organization (WHO) advised against its use, and the COVID vaccines currently on the market have made remdesivir irrelevant to the pandemic. This was just one of Gilead’s recent headwinds. The company worked with Galapagos (GLPG) to develop filgotinib for the treatment of rheumatoid arthritis. While the drug received EU and Japanese approvals in September 2020, the FDA denied approval and Gilead announced in December that it would halt US development efforts for the drug. Even so, Gilead has a diverse and active research pipeline with over 70 research candidates at various stages of development and approval for a variety of diseases and conditions, including HIV / AIDS, & inflammatory respiratory disease, cardiovascular disease, and hematology / oncology. On the positive side, Gilead posted a profit in the third quarter that was above estimates and posted sales of $ 6. 58 billion, beating forecast by 6% and growing 17% year over year. The company updated its full-year 2020 forecast for product sales of 23 billion. USD to 23 billion. USD. 5 billion. Among the bulls is the Oppenheimer analyst Hartaj Singh, who gives GILD shares an outperformance (i. e. Buy) Valuation and $ 100 Target Price. Investors can achieve a 69% profit if the analyst’s thesis prevails. (To see Singh’s track record, click here. ) Singh confirms his stance: “We continue to believe in our thesis of (1) a reliable business with remdesivir / other drugs against SARS-CoV flares, (2) a basic business (HIV) / oncology / HCV) growth in the low single digits in the next few years, (3) operational leverage for higher earnings growth and (4) dividend yield of 3-4%. What is the rest of the street thinking? With regard to the consensus distribution, the opinions of other analysts are more diverse. 10 buys, 12 holds and 1 sell result in a moderate buy consensus. Additionally, those are $ 73. The average target price of 94 shows an upside potential of 25% compared to the current level. (See GILD stock analysis on TipRanks. ) To find great ideas for trading rundown stocks at attractive valuations, visit TipRanks ‘Best Stocks to Buy, a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.

Mobile applications provided by Ant Group, which is supported by Alibaba Group Holding Ltd (NYSE: BABA), will be banned under an executive order passed Tuesday by outgoing President Donald Trump. What happened: U. . S.. . Transactions with Hangzhou, China-based Ant Group Alipay, which had over 1. According to Xinhua, 2 billion users will be banned worldwide as of October 2019. The ordinance will not come into effect until after Trump resigns as it is expected to be applicable in 45 days. Apps offered by Tencent Holdings Ltd (OTC: TCEHY) such as Tencent QQ and WeChatPay were also banned as part of the order, along with CamScanner, SHAREit, VMate and WPS Office. The order underscored the threat posed by Chinese filings that could allow the Asian power to track the location of federal employees and contractors and “create dossiers of personal information”. “Why it matters: Trump’s move is the latest setback for Alibaba, founded by Jack Ma, which is also facing an antitrust investigation in China. See also: Chinese financial regulators urge Ant Group to revise their business Last August, Trump signed an ordinance banning ByteDance’s short-form video app TikTok unless the parent company agreed to sell the app. A federal judge ordered the ban on TikTok to be stopped the following month. Oracle Corp (NASDAQ: ORCL) and Walmart Inc (NYSE: WMT) have agreed to buy TikTok before the court grants relief. According to the latest reports, the Ant Group could be forced to sell part of its stock portfolio. Chinese regulators are also considering asking the fintech company to share consumer data, according to a report in the Wall Street Journal on Tuesday. Price action: Alibaba shares were traded 2. 08% lower at $ 235. 40 in after-hours trading on Tuesday after closing nearly 5. 5% higher at $ 240. 40. For More Information From Benzinga * Click here to receive option trades from Benzinga. * Pinduoduo faces the control as the employee dies after midnight. com. Benzinga does not offer investment advice. All rights reserved.

Although Tesla Inc (NASDAQ: TSLA) is up more than 700% over the past year, it is receiving a bullish call and a new street-high price target. The Tesla Analyst: In a release released after Tuesday’s close of trading, Morgan Stanley analyst Adam Jonas reiterated an overweight position in Tesla and raised the company’s price target from $ 540 to $ 810. Jonas issued a cautious announcement in December describing Apple Inc’s (NASDAQ: AAPL) entry into electric vehicles as a new “bear case” for Tesla. Related link: Morgan Stanley improves Tesla in terms of growth potential in embedded companiesThe Tesla thesis: The 61% year-over-year delivery growth in the fourth quarter was better than Jonas expected. The analyst increased the volume estimate to 5 for 2030. 2 million units from 3. 8 million units. “We continue to believe that Tesla can outperform our sector in 2021,” Jonas wrote in the new note. The analyst said the market had decided to reduce Tesla’s value compared to peers despite a series of high results. “Tesla’s business model can unlock recurring revenue from mobility services faster and more profitably than the competition,” said Jonas, describing Tesla as the “chosen one” for the Internet of cars. It’s hard to find a more innovative company, especially in the electric vehicle and autonomous vehicle market. Jonas described Tesla as the best positioned. TSLA price action: Tesla shares closed 1% to $ 735. 11 on Tuesday. Stocks hit new split-adjusted highs of $ 740. 84 earlier in session. The stock rose 2. 17% up to $ 751 in after-hours trading. Latest Ratings for TSLA DateFirmActionFromTo Jan 2021Exane BNP ParibasDowngradesNeutralUnderperform Jan 2021JP MorganMaintainsUnderweight Dec 2020CFRADowngradesStrong BuyHold See more analyst ratings for TSLA See the latest analyst ratingsSee more from Benzinga * Click here to see options from 2021 Louof electric vehicles sold 11 months ago * 1 Million Ventures Apple comes first among FAANG, a Tesla Robotaxi and a new Peloton equipment (C) 2021 Benzinga. com. Benzinga does not offer investment advice. All rights reserved.

Stock futures were in a waiting loop pattern Tuesday night as traders awaited the results of the Georgia Senate runoff election that will determine control of Congress and influence policy decisions for years to come.

PLUS: The OCC’s green light on banks to use stable coins, Brazil’s booming crypto sector, and the bitcoin mining machine supply crisis.

(Bloomberg) – Zhong Shanshan sets new wealth records. The chairman of Nongfu Spring Co. . , a ubiquitous bottled water company in China, is now richer than Warren Buffett as its net worth has grown by $ 13. 5 billion year-to-date to $ 91. 7 billion on Tuesday, according to the Bloomberg Billionaires Index. The 66-year-old Zhong is the sixth richest person on the planet today. Nongfu stock rose 18% in the first two trading days of 2021, rising to over 200% since it was listed in September. . You won 0. 7% on Wednesday. It’s only the second time a Chinese citizen has broken into the world’s top 10 – real estate tycoon Wang Jianlin beat No.. 8 in 2015 – and no one on the mainland has ranked this high on the Bloomberg Wealth Index since it was launched in 2012. Zhong was locally referred to as a “lone wolf” to avoid involvement in club groups or politics, and also took vaccine maker Beijing Wantai Biological Pharmacy Enterprise Co. . public in April. The stock is down more than 2. 800% increased. Zhong dethroned India’s Mukesh Ambani last week as Asia’s richest person and is on the verge of entering the diluted realm of more than $ 100 billion worth of people. Buffett is outside that group at $ 86. 2 billion fortunes, but Berkshire Hathaway Inc. . The founder has given away more than $ 37 billion worth of shares since 2006. Investors are snatching up Chinese consumer stocks as the country shows it is recovering from Covid-19, while analysts have become increasingly bullish on nongfu. Zhong also helped four relatives become billionaires. His younger sister Zhong Xiaoxiao and three of his wife’s siblings each have a 1. 4% stake in Nongfu valued at $ 1. 3 billion based on the percentage listed in the company’s prospectus from last year. The company has produced dozens of millionaires, including more relatives and employees of Zhong. While Covid-19 turned much of the global economy upside down in 2020, it was a good year for the world’s ultra-rich. The 500 richest people added $ 1. $ 8 trillion in her fortune and together was worth $ 7. 6 trillion by the end of the year. Zhong, the biggest winner from Asia, raised more than $ 71 billion, the most after Tesla Inc.. . Elon Musk and Amazon. com Inc. . Jeff Bezos. A notable exception is Jack Ma, until recently Asia’s richest person. He hasn’t been seen in public since Chinese regulators torpedoed Ant Group Co. IPO valued at $ 35 billion. His net worth has dropped about $ 10 billion since October, and he’s now 25th. richest person in the world. (An earlier version of this story corrected Berkshire’s name in the sixth paragraph and the size of Ant’s IPO in the last paragraph. ) (Updates with Wednesday trains for Nongfu in the third paragraph, Wantai in the fifth paragraph) For more articles like this, please visit us on Bloomberg. comSubscribe now to stay one step ahead with the most trusted business news source. © 2021 Bloomberg L. . P. .

Marriott International, Analysis, Student, Hilton

News – PH – Non-residential student and worker market outlook to 2030 by type, price, channel and booking type
. . Related Title :
COVID-19 Impact Analysis of 2020 Non-Residential Services Market Report 2020 | Marriott International . . .
Market outlook for students and non-residential workers through 2030 by type, price, channel and . . .

Ref: https://finance.yahoo.com